Skip to content Skip to navigation

Definition of AIM-Ready Projects

This page serves as guidance to help Stanford PIs receive clarity on whether their projects may be of interest to the Stanford AIM Review Committee.

Project Scenarios of Interest

  • Novel target/mechanism/phenotype linked to a disease with high unmet medical need and a confirmed hit (any modality utilizing Takeda capability areas)
  • Novel target/mechanism/phenotype linked to a disease with high unmet medical need with no confirmed hits, but with either a robust primary assay ready for HTS optimization, unique expertise from the PI lab for the development of assays or an alternative approach to identifying progress-able hits such as structural modelling and virtual screening approaches
  • Novel¬†chemical biology or biological (therapeutic proteins, gene therapy, antisense and editing, oligonucleotides, cell therapy, oncolytic viruses)¬†approach to an existing target where unmet medical need remains
    • Examples include, but are not limited to (a) allosteric modulators where previous unsuccessful work described orthosteric modulators; (b) irreversible covalent modulators with increased affinity where previous unsuccessful work described reversible non-covalent weak binders; (c) PROTAC degraders for difficult to drug protein-protein interactions (d) Protein, antibody, cellular and genetic approaches to disease modulation
  • Novel combinations, e.g. optimization of the PK of one drug via new chemistry to make it more compatible with its partner drug

Project Scenarios Not Part of AIM Mandate

  • Medical device
  • Diagnostic without associated therapeutic
  • Biomarker without associated therapeutic
  • Use of known non-proprietary tool to identify target/MOA with disease
  • Novel target/phenotype linked to a disease area already well-served by approved medications
  • Reformulations of drugs